- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OSR Health, Inc.: OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission | 318 | ACCESS Newswire | The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc.... ► Artikel lesen | |
| Mi | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| Mi | OSR Health faces Nasdaq delisting over bid-price rule | 1 | Seeking Alpha | ||
| Mi | OSR Health droht NASDAQ-Delisting nach Verstoß gegen Mindestkurs-Anforderung | 1 | Investing.com Deutsch | ||
| Mi | Nasdaq to delist OSR Health after bid price compliance failure | 1 | Investing.com | ||
| Mi | OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal | 871 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination")... ► Artikel lesen | |
| Mi | OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point | 421 | ACCESS Newswire | Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health... ► Artikel lesen | |
| 14.08. | OSR Health, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | Drohendes NASDAQ-Delisting: OSR Health verweist auf Lizenzgespräche | 19 | Investing.com Deutsch | ||
| 11.08. | OSR Health, Inc.: OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development | 693 | ACCESS Newswire | Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today... ► Artikel lesen | |
| 10.08. | OSR Health: Aktionäre bestätigen Vorstand und genehmigen wichtige Anträge auf Hauptversammlung | 7 | Investing.com Deutsch | ||
| 07.08. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | OSR Health, Inc.: OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program | 484 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning... ► Artikel lesen | |
| 03.08. | OSR Health subsidiary completes glioblastoma vaccine analysis | 4 | Investing.com | ||
| 03.08. | OSR Health, Inc.: Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform | 262 | ACCESS Newswire | Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today... ► Artikel lesen | |
| 31.07. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.07. | OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment | 506 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication... ► Artikel lesen | |
| 13.07. | OSR Health, Inc.: OSR Health, A Message From the CEO | 580 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.To Every OSR Health Shareholder:OSR Health... ► Artikel lesen | |
| 02.07. | Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target | 621 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (Nasdaq:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating... ► Artikel lesen | |
| 25.06. | OSR Health, Inc.: OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares | 474 | ACCESS Newswire | Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH)... ► Artikel lesen |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,102 | -5,73 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,845 | +1,43 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 5,812 | +7,99 % | Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA | - New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication - SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| CORMEDIX | 6,862 | -2,22 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 4,040 | +1,05 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates | Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027
Scientific Advisory Board of leading experts in psychiatry and neuroscience established... ► Artikel lesen | |
| REPLIMUNE | 12,360 | -2,18 % | Replimune Group, Inc.: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VALERIO THERAPEUTICS | 0,787 | -6,42 % | Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors | Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV ("Etherna"), and the related contribution agreement, based on an enterprise value of €30 million... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,879 | -0,08 % | H.C. Wainwright bekräftigt Kaufempfehlung für Rani Therapeutics Aktie | ||
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 36,360 | +6,25 % | H.C. Wainwright hebt Kursziel für Alto Neuroscience auf 55 US-Dollar an | ||
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment | Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies... ► Artikel lesen | |
| CG ONCOLOGY | 78,23 | -1,98 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| QIAGEN | 36,405 | -3,09 % | XETRA-SCHLUSS/Knapp behauptet - Qiagen nach CEO-Wechsel gemieden | DJ XETRA-SCHLUSS/Knapp behauptet - Qiagen nach CEO-Wechsel gemieden
DOW JONES--Der deutsche Aktienmarkt hat am Montag mit leichten Verlusten geschlossen. Trotz des wieder deutlich unter 1,17 Dollar... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,330 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen |
Das Unternehmen OSR HEALTH INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,254 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HEALTH INC finden Sie auf Wallstreet Online.